医学
化疗
病态的
磁共振成像
生物标志物
动态对比度
癌
新辅助治疗
放射科
膀胱癌
动态增强MRI
病理
泌尿科
核医学
癌症
内科学
化学
乳腺癌
生物化学
作者
Camille Chakiba,F. Cornelis,E. Descat,Marine Gross‐Goupil,Paul Sargos,Guilhem Roubaud,Nadine Houédé
标识
DOI:10.1016/j.ejrad.2015.02.026
摘要
Objectives To evaluate the performance of dynamic contrast enhanced (DCE) magnetic resonance (MR) imaging to assess the histological response after chemotherapy on bladder carcinoma. Methods From 2008 to 2010, 12 patients presenting localized urothelial carcinoma of the bladder were prospectively evaluated by DCE-MR imaging before and after two courses of cisplatin-based neoadjuvant chemotherapy. Size and thickness of tumours were measured. Relative enhancement at the arterial (rSI35s) and venous phases (rSI80s) of each tumour was obtained. Histological response was assessed and outcomes were recorded. Results Histological examination after neoadjuvant chemotherapy concluded as pathological complete response (pCR) for 6 out of 12 patients. Five patients developed recurrences (4/6 no pCR and 1/6 pCR). Significant differences, between before and after treatment, were found for patients with complete pathological response after chemotherapy for all MR quantitative values. Tumours decreased in size and thickness (both P = 0.03). After treatment, rSI80s was significantly different between pCR and non-pCR patients (P = 0.04) with a cut-off value of 40%. For this cut-off, sensitivity, specificity and accuracy were 83.33%. Similar recurrence free survivals were obtained if applying the MR cut-off value or the histopathological findings. Conclusion Our results suggest that DCE-MR imaging may be a useful biomarker for patients with localized bladder carcinoma, improving selection before surgery.
科研通智能强力驱动
Strongly Powered by AbleSci AI